Log in to your Inderes Free account to see all free content on this page.
Intervacc
1.14 SEK
-0.70 %
Less than 1K followers
IVACC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Intervacc
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 12.1 | 4.8 | 5.2 | 9.7 | 8.0 | 11.8 | 20.1 |
| growth-% | -60.6 % | 9.6 % | 84.7 % | -17.1 % | 47.0 % | 70.4 % | |
| EBITDA | -21.7 | -19.5 | -23.2 | -43.6 | -69.0 | -58.8 | -64.9 |
| EBIT | -27.8 | -25.7 | -29.4 | -64.4 | -93.6 | -77.3 | -83.5 |
| Profit before taxes | -27.9 | -25.6 | -29.4 | -64.2 | -91.5 | -75.5 | -80.8 |
| Net income | -27.9 | -25.6 | -29.4 | -64.2 | -102.9 | -75.5 | -80.8 |
| EPS | -0.53 | -0.38 | -0.44 | -0.95 | -1.45 | -0.86 | -0.27 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -178.7 % | -408.0 % | -443.4 % | -450.0 % | -860.1 % | -498.3 % | -323.1 % |
| EBIT-% | -229.4 % | -537.2 % | -560.8 % | -665.4 % | -1,166.8 % | -655.5 % | -415.7 % |
| ROE | -12.7 % | -7.6 % | -9.5 % | -25.6 % | -43.2 % | -46.5 % | -29.4 % |
| ROI | -11.8 % | -7.2 % | -8.9 % | -24.2 % | -39.6 % | -40.3 % | -27.4 % |
Login required
This content is only available for logged in users